美康生物科技股份有限公司 2023 年半年度 非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 | 上市公司核算的 | 2023 年期初 | 2023 年 1-6月占用累计 | 2023 年 1-6月占用资 | 2023 年 1-6月偿还 | 2023 年半年度期 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 司的关联关系 | 会计科目 | 占用资金余额 | 发生金额（不含利息） | 金的利息（如有） | 累计发生金额 | 末占用资金余额 | 原因 | | | 控股股东、实际控制人 | | | | | | | | | | | | 及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、实际控制 | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | ...

美康生物科技股份有限公司 证券代码：300439 证券简称：美康生物 公告编号：2023-056 美康生物科技股份有限公司 关于为全资孙公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 美康生物科技股份有限公司（以下简称"公司"）于 2023 年 8 月 18 日召开 公司第四届董事会第十九次会议，审议通过了《关于为全资孙公司提供担保的议 案》。具体情况如下： 一、本次担保情况概述 具体内容详见刊登在中国证券监督管理委员会指定的创业板信息披露网站上的 相关公告（公告编号 2021-047、2021-049）。 上述《担保协议》中指出"担保方在本合同项下的保证期间为本担保合同生 效之日起五年。若在前述担保期限内担保方及关联方与罗氏签订新的《担保合同》 以替代本《担保合同》，则自新的《担保合同》生效之日起本《担保合同》自动 终止"。鉴于本次公司与罗氏签署了新的《担保合同》，则原《担保合同》自动 终止，即自新的《担保合同》生效之日起，盛达生物不再为德胜生物承担相关连 带的保证责任。 三、被担保方基本情况 鉴于全资孙公司宁波德胜生物技术有限公司（以下 ...

美康生物科技股份有限公司 证券代码：300439 证券简称：美康生物 公告编号：2023-050 美康生物科技股份有限公司 第四届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 美康生物科技股份有限公司（以下简称"公司"）第四届董事会第十九次会 议于 2023 年 8 月 18 日在公司会议室以现场结合通讯方式召开，会议通知已于 2023 年 8 月 8 日以电话、邮件等方式送达全体董事。会议应出席董事 5 人，实 际出席董事 5 人，会议由董事长邹炳德先生召集并主持。本次会议的召集、召开 符合《中华人民共和国公司法》、《美康生物科技股份有限公司章程》的有关规 定，合法有效。 经与会董事审议与表决，通过了如下议案： 一、审议并一致通过《关于公司<2023 年半年度报告>及其摘要的议案》 公司编制了《2023 年半年度报告全文》及《2023 年半年度报告摘要》。公 司 2023 年半年度报告及摘要的内容真实、准确、完整地反映了公司 2023 年半年 度经营的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见同日刊登在 ...

美康生物科技股份有限公司 美康生物科技股份有限公司独立董事 关于第四届董事会第十九次会议相关事项的独立意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《深圳证券 交易所创业板上市公司规范运作指引》及《美康生物科技股份有限公司章程》（以 下简称"《公司章程》"）的规定，作为美康生物科技股份有限公司（以下简称 "公司"）第四届董事会的独立董事，我们本着认真、严谨、负责的态度，基于 独立判断的立场，审阅了公司第四届董事会第十九次会议审议的相关议案的会议 材料及具体议案内容，现发表以下独立意见：： 一、关于公司控股股东及其他关联方占用资金、对外担保情况的专项说明 及独立意见 我们对公司 2023 年上半年控股股东及其他关联方占用公司资金和公司对外 担保情况，进行了认真负责的核查，现发表独立意见如下： 1、报告期内，公司不存在控股股东及其他关联方非经营性占用公司资金的 情况，也不存在以前年度发生并累计至报告期的违规关联方占用资金情形。 准确、完整，不存在虚假记录、误导性陈述和重大遗漏。 因此，我们一致同意公司董事会编制的《2023 年半年度募集资金存放与使 用情况的专项报告》。 三、关于向全资子公司划转相 ...

美康生物科技股份有限公司 证券代码：300439 证券简称：美康生物 公告编号：2023-054 美康生物科技股份有限公司 2023 年半年度募集资金存放与使用情况 的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会发布的《上市公司监管指引第2号——上市公 司募集资金管理和使用的监管要求》和深圳证券交易所颁布的《深圳证券交易所 上市公司自律监管指引第2号——创业板上市公司规范运作》以及《深圳证券交易 所创业板上市公司自律监管指南第2号——公告格式》的相关规定，本公司将2023 年半年度的募集资金存放与使用情况作如下专项报告： 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 经中国证券监督管理委员会证监许可[2021]310号文"关于同意美康生物科技 股份有限公司向特定对象发行股票注册的批复"核准，同意公司向特定对象发行 39,999,995股人民币普通股（A股），每股发行价为人民币15.00元，共募集资金人 民币599,999,925.00元。截至2021年3月17日止，公司实际已发行人民币普通股（A 股）39, ...

美康生物科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 美康生物科技股份有限公司（以下简称"公司"）分别于 2023 年 4 月 24 日、 2023 年 5 月 19 日召开第四届董事会第十六次会议及 2022 年年度股东大会，审 议通过了《关于 2023 年度为全资子公司提供担保额度预计的议案》，同意公司 为宁波美康盛达生物科技有限公司（以下简称"盛达生物"）、宁波美康盛德生 物科技有限公司（以下简称"盛德生物"）融资授信提供担保，预计总担保额度 不超过人民币 10,000 万元（含本数）。其中，公司为最近一期资产负债率 70% 以上的全资子公司盛达生物提供担保的额度预计不超过人民币 6,000 万元，公司 为最近一期资产负债率 70%以下的全资子公司盛德生物提供担保的额度预计不 超过人民币 4,000 万元。具体内容详见刊登在中国证监会指定的创业板信息披露 网站上的相关公告（公告编号：2023-026）。 二、担保进展情况 近日，公司与中国民生银行股份有限公司宁波分行签署了《最高额保证合同》， 为上述全资子公司盛达生物 ...

美康生物科技股份有限公司 关于向全资子公司划转相关资产暨增资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次划转及增资概述 1、为优化公司管理和业务架构，提高公司整体经营管理效率，美康生物科 技股份有限公司（以下简称"公司"或"美康生物"）拟将其位于宁波市鄞州区 下应街道姜村村处的土地25,307平方米及地上在建建筑物等资产依据评估作价 向全资子公司宁波瑞合院生物科技有限公司（以下简称"宁波瑞合院"）进行增 资。上述事项实施完毕后，宁波瑞合院将成为上述资产的运营主体。 2、2023年8月18日，公司召开第四届董事会第十九次会议，会议审议通过了 《关于向全资子公司划转相关资产暨增资的议案》。根据《深圳证券交易所创业 板股票上市规则》《美康生物科技股份有限公司章程》（以下简称"《公司章程》"） 及公司《对外投资管理制度》等规章制度的相关规定，本次增资事项属于董事会 决策范围，无需提交股东大会审议。 证券代码：300439 证券简称：美康生物 公告编号：2023-055 美康生物科技股份有限公司 3、本次交易属于公司内部划转，不涉及关联交易，不构成《 ...

美康生物科技股份有限公司 证券代码：300439 证券简称：美康生物 美康生物科技股份有限公司 投资者关系活动记录表 编号：2023-01 投资者关系活动 √特定对象调研 □分析师会议 类别 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称及 1、网上业绩说明会：通过全景网参会的网上投资者及网友 人员姓名 2、特定对象调研：金元证券 胡凤龙、王光军、王亦林；毫木资本 徐凤仙等 时间 1、网上业绩说明会：2023 年 5 月 12 日（星期五）下午 15:00-17:00 2、特定对象调研：2023 年 5 月 5 日（星期五）下午 14:00-15:00 地点 1、网上业绩说明会：公司通过全景网"投资者关系互动平台" （https://ir.p5w.net）采用网络远程的方式召开业绩说明会 2、特定对象调研：公司会议室召开特定对象调研 上市公司接待人 1、业绩说明会参加人员：董事长邹炳德、总经理兼董事邹继华、 员姓名 独立董事李成艾、财务总监兼董事会秘书熊慧萍、保荐代表人 钟亚桢 2、特定对象调研参加人员：投资者关系主管徐殷笙 公司主要就 2022 年度及 2023 年第一 ...

Revenue and Profit - The company's revenue for Q1 2023 was ¥490,894,873.63, a decrease of 14.99% compared to ¥577,448,213.25 in the same period last year[4] - Net profit attributable to shareholders was ¥71,413,144.40, representing a 2.66% increase from ¥69,561,237.21 year-on-year[4] - The company achieved operating revenue of RMB 490.89 million, a year-on-year decrease of 14.99%, while self-produced product revenue increased by 36.94%[15] - The net profit attributable to shareholders was RMB 71.41 million, a year-on-year increase of 2.66%, and the net profit after deducting non-recurring gains and losses was RMB 56.61 million, up 7.17%[15] - The total profit for the current period is 76,474,872.82, a decrease from 80,181,917.66 in the previous period, representing a decline of approximately 8.5%[28] - The net profit for the current period is 69,653,541.35, an increase from 67,966,450.42 in the previous period, reflecting a growth of about 2.5%[28] Cash Flow and Financial Position - The net cash flow from operating activities improved significantly to ¥60,351,999.25, a 170.60% increase from a negative cash flow of ¥85,484,991.87 in the previous year[4] - Cash and cash equivalents at the end of the period were CNY 773,538,041.68, down from CNY 806,412,812.69 at the beginning of the year[21] - Total current assets decreased to CNY 1,953,598,972.99 from CNY 2,071,549,435.51, reflecting a reduction of approximately 5.7%[21] - Total liabilities decreased to CNY 902,656,201.09 from CNY 1,064,233,390.98, indicating a reduction of about 15.2%[22] - The company's total equity increased to CNY 2,570,393,299.96 from CNY 2,519,443,027.42, showing a growth of approximately 2%[22] - The cash inflow from operating activities totals 587,144,370.21, down from 606,069,599.01 in the previous period[31] - The cash outflow from investing activities is 205,541,105.18, compared to 160,261,855.94 in the previous period, indicating an increase in investment expenditures[31] - The net cash flow from financing activities is -72,062,091.34, a decrease from -4,839,993.00 in the previous period, reflecting increased cash outflows for debt repayment[33] Earnings and Expenses - Basic and diluted earnings per share increased by 5.56% to ¥0.19 from ¥0.18 in the same period last year[4] - The overall gross margin increased by 1.12 percentage points compared to the same period last year due to a higher proportion of self-produced products, which have a higher gross margin than inspection services and agency products[15] - Financial expenses decreased significantly by 96.51% to ¥185,138.93 from ¥5,298,721.95 due to reduced bank borrowings[10] - Research and development expenses for the quarter were CNY 38,701,417.42, up from CNY 35,417,855.98, reflecting a focus on innovation[26] - The tax expenses for the current period are 6,821,331.47, down from 12,215,467.24 in the previous period, showing a reduction of approximately 44%[28] Asset Management and Investments - Total assets decreased by 3.09% to ¥3,473,049,501.05 from ¥3,583,676,418.40 at the end of the previous year[4] - Shareholders' equity attributable to the parent company increased by 2.85% to ¥2,581,656,450.32 from ¥2,510,065,477.78 at the end of the previous year[4] - The balance of accounts receivable decreased compared to the same period last year, leading to a 246.52% reduction in credit impairment losses[15] - The company transferred 51% equity of Inner Mongolia Shengde for a total price of RMB 14.28 million, and will no longer consolidate Inner Mongolia Shengde into its financial statements[18] - The company signed an agreement to transfer 70% equity of Chongqing Runkang Bio-Tech for a total price of RMB 3.045 million, which will impact the company's 2023 profit by approximately RMB 1.98 million[19] - The actual controller, Zou Bingde, transferred 19,149,991 shares (5% of total shares) to Chen Chaohong at a price of RMB 9.35 per share, totaling RMB 179.05 million[16] - As of the report date, the company had received RMB 4.53 million from the equity transfer of Inner Mongolia Shengde[18] - Zou Bingde released 8 million shares from pledge, leaving 11 million shares still pledged[17] Strategic Outlook - The company aims to expand its market presence and enhance product offerings in the upcoming quarters[27]

Financial Performance - The company's operating revenue for 2022 was ¥2,489,086,216.22, representing a 10.55% increase compared to ¥2,251,532,206.94 in 2021[19]. - The net profit attributable to shareholders for 2022 was ¥198,527,038.64, up 10.61% from ¥179,488,034.18 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was ¥170,266,305.71, a slight increase of 1.57% from ¥167,626,310.44 in 2021[19]. - The net cash flow from operating activities was ¥564,665,289.18, reflecting a 9.54% increase from ¥515,482,463.26 in the prior year[19]. - The total assets at the end of 2022 were ¥3,583,676,418.40, a decrease of 0.26% from ¥3,593,187,118.77 at the end of 2021[19]. - The net assets attributable to shareholders increased by 6.95% to ¥2,510,065,477.78 from ¥2,347,016,911.96 in 2021[19]. - The basic earnings per share for 2022 were ¥0.52, an increase of 8.33% compared to ¥0.48 in 2021[19]. - The diluted earnings per share also stood at ¥0.52, reflecting the same 8.33% growth from the previous year[19]. - The weighted average return on equity was 8.20%, slightly down from 8.36% in 2021[19]. - The company achieved total revenue of CNY 248,908.62 million, a year-on-year increase of 10.55%[43]. Dividend Distribution - The company plans to distribute a cash dividend of 1.05 CNY per 10 shares to all shareholders, based on a total of 382,999,815 shares[3]. - The company plans to distribute a cash dividend of 1.05 yuan (including tax) for every 10 shares, with a total cash dividend amounting to 40,214,980.58 yuan, which represents 100% of the total profit distribution[156]. - The total number of shares for the dividend distribution is based on 382,999,815 shares, with no stock dividends or capital reserve transfers planned[157]. Market and Industry Insights - The global in vitro diagnostics (IVD) market size reached $127.4 billion in 2022, with a projected growth to $140 billion by 2027 at a CAGR of 2%[29]. - China's IVD market size was approximately $15.5 billion in 2021, reflecting a year-on-year growth of 17.08%[29]. - The independent clinical laboratory (ICL) industry in China has grown from 89 ICLs in 2010 to 1,966 ICLs by June 2021, with a compound annual growth rate (CAGR) of 32.49%[33]. - The market size of the ICL industry (excluding COVID-19 testing) increased from 14.7 billion CNY in 2017 to 22.3 billion CNY in 2021, with an expected CAGR of 18.2% from 2021 to 2026, reaching 51.3 billion CNY[33]. - The domestic in vitro diagnostic market is expected to benefit from accelerated domestic substitution and increased demand due to aging population and rising healthcare spending[32]. Research and Development - R&D investment reached CNY 17,178.37 million, an increase of 14.00% year-on-year, emphasizing the company's commitment to innovation[43]. - The company reported R&D expenditure of ¥171,783,728.65 in 2022, an increase from ¥150,683,995.48 in 2021, representing a growth of 14.05%[79]. - R&D expenditure accounted for 6.90% of total revenue in 2022, up from 6.69% in 2021[79]. - The number of R&D personnel increased to 402 in 2022, a rise of 6.35% from 378 in 2021[78]. - The company has applied for 383 patents in China, with 269 granted, and 15 patents applied for overseas, with 5 granted[83]. Product Development and Innovation - The company is focusing on advanced diagnostic technologies such as molecular diagnostics and chemiluminescent immunoassays, as encouraged by national policies[31]. - The company launched several new products, including specific growth factor test kits and a compact chemiluminescence analyzer, enhancing its product line[44]. - The company is currently conducting clinical trials for several test kits, including those for soluble growth stimulation expressed gene 2 protein and reverse triiodothyronine, which may enhance its diagnostic capabilities[80]. - The company is pursuing regulatory approvals for various hepatitis-related test kits, which could significantly impact its market presence in infectious disease diagnostics[80]. - The company is expanding its product line with new diagnostic tests, including those for infectious diseases and hormone detection, to enhance brand influence[76]. Strategic Focus and Growth Opportunities - The company has identified significant growth opportunities in the emerging markets, driven by increasing healthcare investments and rising per capita medical spending[30]. - The company aims to enhance its market presence through the introduction of new technologies and products in the coming years[81]. - The company plans to enhance its innovation capabilities in in vitro diagnostic reagents, instruments, and raw materials, focusing on new products like the integrated immunoassay machine and mass spectrometry[112]. - The company aims to strengthen its market position in the IVD industry, targeting leadership in biochemical diagnostics and mass spectrometry, as well as pioneering domestic special inspection services[112]. - The company is exploring potential mergers and acquisitions to bolster its competitive edge in the diagnostics market[81]. Compliance and Governance - The company has established a comprehensive governance structure, including a board of directors and various specialized committees, to ensure effective decision-making and oversight[129]. - The company has maintained independence from its controlling shareholders in terms of assets, personnel, and operations, ensuring autonomous business capabilities[131]. - The company will continue to strengthen its compliance and governance practices in line with relevant laws and regulations[130]. - The company has established a comprehensive internal control management system to enhance compliance and governance, ensuring effective oversight of subsidiaries and investments[159]. - The company has implemented a cash dividend distribution that aligns with the company's articles of association and dividend management policies, ensuring transparency and compliance[156]. Legal and Regulatory Matters - The company is involved in significant litigation, with a claim amounting to RMB 53,630,027.29 related to a breach of agreement by a shareholder[190]. - The company has received a civil judgment from the Ningbo Intermediate Court regarding the Wuhan Anhe Rui contract dispute, with the case still under appeal[190]. - The company is actively pursuing legal actions to recover funds from various parties, including a claim for RMB 25,836,925.08 against Wuhan Anhe Rui[190]. - The company has reported that the litigation process is ongoing, with no final judgment reached as of the report date[190]. - The company is facing multiple lawsuits, with the Ningbo Intermediate Court and the Yinzhou District Court handling different cases[190].